Revisiting the Design of Phase III Clinical Trials of Antimalarial Drugs for Uncomplicated Plasmodium falciparum Malaria

Steffen Borrmann and colleagues discuss appropriate endpoints and their measurement during phase III trials of new antimalarial drugs.

Detalles Bibliográficos
Autores principales: Borrmann, Steffen, Peto, Tim, Snow, Robert W, Gutteridge, Win, White, Nicholas J
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2008
Materias:
Policy Forum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2586344/
https://www.ncbi.nlm.nih.gov/pubmed/19018658
http://dx.doi.org/10.1371/journal.pmed.0050227
_version_ 1782160889163546624
author Borrmann, Steffen
Peto, Tim
Snow, Robert W
Gutteridge, Win
White, Nicholas J
author_facet Borrmann, Steffen
Peto, Tim
Snow, Robert W
Gutteridge, Win
White, Nicholas J
author_sort Borrmann, Steffen
collection PubMed
description Steffen Borrmann and colleagues discuss appropriate endpoints and their measurement during phase III trials of new antimalarial drugs.
format Text
id pubmed-2586344
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-25863442008-11-25 Revisiting the Design of Phase III Clinical Trials of Antimalarial Drugs for Uncomplicated Plasmodium falciparum Malaria Borrmann, Steffen Peto, Tim Snow, Robert W Gutteridge, Win White, Nicholas J PLoS Med Policy Forum Steffen Borrmann and colleagues discuss appropriate endpoints and their measurement during phase III trials of new antimalarial drugs. Public Library of Science 2008-11 2008-11-18 /pmc/articles/PMC2586344/ /pubmed/19018658 http://dx.doi.org/10.1371/journal.pmed.0050227 Text en © 2008 Borrmann et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Policy Forum
Borrmann, Steffen
Peto, Tim
Snow, Robert W
Gutteridge, Win
White, Nicholas J
Revisiting the Design of Phase III Clinical Trials of Antimalarial Drugs for Uncomplicated Plasmodium falciparum Malaria
title Revisiting the Design of Phase III Clinical Trials of Antimalarial Drugs for Uncomplicated Plasmodium falciparum Malaria
title_full Revisiting the Design of Phase III Clinical Trials of Antimalarial Drugs for Uncomplicated Plasmodium falciparum Malaria
title_fullStr Revisiting the Design of Phase III Clinical Trials of Antimalarial Drugs for Uncomplicated Plasmodium falciparum Malaria
title_full_unstemmed Revisiting the Design of Phase III Clinical Trials of Antimalarial Drugs for Uncomplicated Plasmodium falciparum Malaria
title_short Revisiting the Design of Phase III Clinical Trials of Antimalarial Drugs for Uncomplicated Plasmodium falciparum Malaria
title_sort revisiting the design of phase iii clinical trials of antimalarial drugs for uncomplicated plasmodium falciparum malaria
topic Policy Forum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2586344/
https://www.ncbi.nlm.nih.gov/pubmed/19018658
http://dx.doi.org/10.1371/journal.pmed.0050227
work_keys_str_mv AT borrmannsteffen revisitingthedesignofphaseiiiclinicaltrialsofantimalarialdrugsforuncomplicatedplasmodiumfalciparummalaria
AT petotim revisitingthedesignofphaseiiiclinicaltrialsofantimalarialdrugsforuncomplicatedplasmodiumfalciparummalaria
AT snowrobertw revisitingthedesignofphaseiiiclinicaltrialsofantimalarialdrugsforuncomplicatedplasmodiumfalciparummalaria
AT gutteridgewin revisitingthedesignofphaseiiiclinicaltrialsofantimalarialdrugsforuncomplicatedplasmodiumfalciparummalaria
AT whitenicholasj revisitingthedesignofphaseiiiclinicaltrialsofantimalarialdrugsforuncomplicatedplasmodiumfalciparummalaria

Ejemplares similares